Search Results

U.S. Army Institute of Surgical Research to conduct key studies intended to further our knowledge of the effects of Claromer technology

Smith+Nephew, the global medical technology company, announced they have entered into a Master Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research.

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that novel, twice daily, oral opaganib[1], delivered a statistically significant increase in survival time when given at 150 mg/kg twice a day (BID) in a United States Army Medical Research Institute of Infectious Diseases (USAMRIID) in vivo Ebola virus study, making it the first host-directed molecule to show activity in Ebola virus disease.

Virpax Pharmaceuticals Announces Preliminary Results of Probudur TM Pilot Study with the U.S. Army Institute of Surgical Research.

- Company listed in Research and Markets’ announcement and description of new research report on the U.S. Breast Cancer Screening and Diagnostic Market- - “U.S. breast cancer screening and diagnostic [device] market was valued at $1.55 billion in 2024 and is anticipated to reach $2.34 billion by the end of 2030, at a CAGR of 7.05% during the forecast period 2024-20301"- -Report supports Company’s regulatory strategy for IzoView Breast CT, reinforces high demand for new breast imaging modalities, strengthens the potential for rapid market adoption and significant market share -

RION, a leading clinical-stage regenerative medicine company, announced that it will collaborate with Mayo Clinic and the U.S. Army Medical Research Institute for Chemical Defense on a $2.4M grant awarded from the Department of Defense.

Virpax ® Pharmaceuticals, Inc. today announced that the cooperative research and development agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) to evaluate Virpax’s Probudur™, an injectable long-acting liposomal bupivacaine formulation that is injected at the wound site, has been extended to September of 2024.

U.S. Naval Infectious Diseases Diagnostic Laboratory to study dengue fever activity of Claromer antiviral compounds, combatting a rapidly growing mosquito-borne viral infection and a national priority biodefense threat